Results 261 to 270 of about 64,512 (289)
Some of the next articles are maybe not open access.
Small-Molecule MDM2 Inhibitors in Clinical Trials for Cancer Therapy
European Journal of Medicinal Chemistry, 2022Fen-Er Chen
exaly
Proceedings of the National Academy of Sciences of the United States of America, 2021
Baktiar Karim +2 more
exaly
Baktiar Karim +2 more
exaly
2020
Interaction between p53 and the E3 ubiquitin ligase murine double minute 2 homolog (MDM2) is regarded as an important target for anticancer therapeutics. The p53/MDM2 protein-protein interaction is one of the best-studied and most targeted intracellular processes related to cancer progression.
openaire +1 more source
Interaction between p53 and the E3 ubiquitin ligase murine double minute 2 homolog (MDM2) is regarded as an important target for anticancer therapeutics. The p53/MDM2 protein-protein interaction is one of the best-studied and most targeted intracellular processes related to cancer progression.
openaire +1 more source
Stress-Activated NRF2-MDM2 Cascade Controls Neoplastic Progression in Pancreas
Cancer Cell, 2017Debanjan Dhar +2 more
exaly
BAI1 Suppresses Medulloblastoma Formation by Protecting p53 From Mdm2-Mediated Degradation
Cancer Cell, 2018George Gillespie +2 more
exaly
The Deubiquitinating Enzyme USP2a Regulates the p53 Pathway by Targeting Mdm2
EMBO Journal, 2007Dimitris P Xirodimas +2 more
exaly
Mdm2 Haplo‐Insufficiency Profoundly Inhibits Myc‐Induced Lymphomagenesis
EMBO Journal, 2003John L Cleveland, Christine M Eischen
exaly

